BiondVax Pharmaceuticals (NASDAQ:BVXV) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.

Shares of BiondVax Pharmaceuticals (BVXV) traded down $0.31 during mid-day trading on Friday, reaching $5.51. The company’s stock had a trading volume of 10,275 shares, compared to its average volume of 45,151. BiondVax Pharmaceuticals has a 52-week low of $3.04 and a 52-week high of $10.75.

TRADEMARK VIOLATION NOTICE: “BiondVax Pharmaceuticals (BVXV) Downgraded by ValuEngine to “Sell”” was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/biondvax-pharmaceuticals-bvxv-downgraded-by-valuengine-to-sell/1738120.html.

About BiondVax Pharmaceuticals

BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.

Receive News & Ratings for BiondVax Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.